المؤلفون: V. B. Vasilyuk, A. Yu. Boroduleva, P. D. Sobolev, A. G. Nikiforova, V. G. Mozgovaya, O. V. Filon, A. V. Zinkovskaya, V. G. Ignatiev, M. Yu. Samsonov, I. S. Kozlova, E. K. Khanonina

المصدر: Фармация и фармакология (Пятигорск), Vol 10, Iss 6, Pp 562-572 (2023)

مصطلحات موضوعية: covid-19, молнупиравир, биоэквивалентность, фармакокинетика, n-гидроксицитидин, Therapeutics. Pharmacology, RM1-950

وصف الملف: electronic resource

العلاقة: https://www.pharmpharm.ru/jour/article/view/1221Test; https://doaj.org/toc/2307-9266Test; https://doaj.org/toc/2413-2241Test

الوصول الحر: https://doaj.org/article/91d7a9f6654b4e59a0ac406a9eb82ad6Test

المؤلفون: E. V. Tavlueva, E. V. Zernova, M. P. Kutepova, N. E. Kostina, V. S. Lesina, D. R. Mould, K. Ito, A. V. Zinchenko, A. N. Dolgorukova, M. V. Nikolskaya, M. S. Lemak, O. V. Filon, M. Yu. Samsonov

المصدر: Фармация и фармакология (Пятигорск), Vol 10, Iss 5, Pp 460-471 (2022)

مصطلحات موضوعية: covid-19, олокизумаб, клиренс, фармакокинетическая модель, Therapeutics. Pharmacology, RM1-950

وصف الملف: electronic resource

العلاقة: https://www.pharmpharm.ru/jour/article/view/1196Test; https://doaj.org/toc/2307-9266Test; https://doaj.org/toc/2413-2241Test

الوصول الحر: https://doaj.org/article/96b8864adb544463a121630b4d6598a5Test

المؤلفون: E. V. Shipaeva, O. V. Filon, A. V. Zintchenko, G. A. Shipunov, A. A. Dmitrieva, M. S. Lemak, S. A. Grishin, E. I. Trofimets, K. L. Kryshen, L. I. Kozlovskaya, A. S. Lunin, V. D. Apolokhov, S. F. Barbashov, Ya. V. Lavrovsky, M. Yu. Samsonov

المصدر: Биопрепараты: Профилактика, диагностика, лечение, Vol 22, Iss 4, Pp 414-434 (2022)

مصطلحات موضوعية: sars-cov-2, molnupiravir, rph-137, vero cell culture, syrian hamsters, efficacy, rt-pcr, Biotechnology, TP248.13-248.65, Medicine

وصف الملف: electronic resource

العلاقة: https://www.biopreparations.ru/jour/article/view/437Test; https://doaj.org/toc/2221-996XTest; https://doaj.org/toc/2619-1156Test

الوصول الحر: https://doaj.org/article/b6498fb9f9704919973eae259a4a5c4eTest

المؤلفون: E. S. Kuvardin, D. Yu. Andreev, P. A. Yastrebov, V. Yu. Myachikova, D. V. Bukhanova, D. V. Karpova, K. N. Malikov, M. Yu. Samsonov, A. L. Maslyanskiy

المصدر: Научно-практическая ревматология, Vol 60, Iss 5, Pp 603-608 (2022)

مصطلحات موضوعية: systemic sclerosis, olokizumab, interleukin - 6, Diseases of the musculoskeletal system, RC925-935

وصف الملف: electronic resource

العلاقة: https://rsp.mediar-press.net/rsp/article/view/3230Test; https://doaj.org/toc/1995-4484Test; https://doaj.org/toc/1995-4492Test

الوصول الحر: https://doaj.org/article/74c94962383a46af9b50fe955058831bTest

المؤلفون: E. L. Nasonov, M. Yu. Samsonov

المصدر: Научно-практическая ревматология, Vol 60, Iss 3, Pp 280-298 (2022)

مصطلحات موضوعية: systemic autoinflammatory diseases, interleukin 1, anakinra, covid-19, Diseases of the musculoskeletal system, RC925-935

وصف الملف: electronic resource

العلاقة: https://rsp.mediar-press.net/rsp/article/view/3172Test; https://doaj.org/toc/1995-4484Test; https://doaj.org/toc/1995-4492Test

الوصول الحر: https://doaj.org/article/b8af1bc3439d4d0b8d3bbe9f69b9fdabTest

المؤلفون: M. A. Kolganova, N. S. Bagaeva, Yu. V. Medvedev, I. E. Shohin, A. V. Demchinskaya, T. N. Palkina, D. A. Salazanov, G. E. Konopleva, M. S. Sheremeteva, Sh. Z. Archuadze, Ya. V. Lavrovsky, A. Yu. Savchenko, M. Yu. Samsonov

المصدر: Разработка и регистрация лекарственных средств, Vol 8, Iss 3, Pp 91-100 (2019)

مصطلحات موضوعية: бевацизумаб, иммуногенность, фармакокинетика, препараты-биоаналоги, биоэквивалентность, иммуноферментный анализ., Pharmaceutical industry, HD9665-9675

وصف الملف: electronic resource

العلاقة: https://www.pharmjournal.ru/jour/article/view/707Test; https://doaj.org/toc/2305-2066Test; https://doaj.org/toc/2658-5049Test

الوصول الحر: https://doaj.org/article/6934a7f8205e43d19cd8c3495b30f189Test

المؤلفون: K. L. Kryshen, A. A. Muzhikyan, D. S. Gaidai, K. O. Zaikin, A. E. Katelnikova, M. Yu. Samsonov, E. I. Mukhametshina, G. E. Konopleva, E. V. Shipaeva, A. A. Dmitrieva, F. S. Shagiakhmetov, A. O. Popova, M. N. Makarova, V. G. Makarov

المصدر: Issledovaniâ i Praktika v Medicine, Vol 6, Iss 2, Pp 58-68 (2019)

مصطلحات موضوعية: алкогольная зависимость, антагонисты опиатных рецепторов, онделопран, канцерогенность, частота возникновения опухолей, крысы, Medicine

وصف الملف: electronic resource

العلاقة: https://www.rpmj.ru/rpmj/article/view/400Test; https://doaj.org/toc/2410-1893Test

الوصول الحر: https://doaj.org/article/cc97aa7303954c77ba50c93ca8d5605dTest

المؤلفون: M. V. Mayevskaya, V. T. Ivashkin, O. O. Znoyko, Ye. A. Klimova, D. T. Abdurakhmanov, I. G. Bakulin, P. O. Bogomolov, E. Z. Burnevich, M. Yu. Galushko, N. I. Geyvandova, K. V. Zhdanov, Ye. V. Esaulenko, S. N. Kizhlo, D. Yu. Konstantinov, N. I. Mironova, V. G. Morozov, Ye. A. Strebkova, I. G. Nikitin, M. F. Osipenko, V. D. Pasechnikov, O. I. Sagalova, I. M. Khayertynova, V. P. Chulanov, A. A. Yakovlev, I. A. Vasyutin, Ye. P. Tarkhova, E. N. Krasavina, M. Yu. Samsonov

المصدر: Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 27, Iss 6, Pp 41-51 (2018)

مصطلحات موضوعية: хронический гепатит с, лечение, нарлапревир, Diseases of the digestive system. Gastroenterology, RC799-869

وصف الملف: electronic resource

العلاقة: https://www.gastro-j.ru/jour/article/view/191Test; https://doaj.org/toc/1382-4376Test; https://doaj.org/toc/2658-6673Test

الوصول الحر: https://doaj.org/article/0686acb179664d0d893a6a2414c4957cTest

المؤلفون: D. S. Fomina, S. S. Andreev, G. V. Andrenova, T. S. Kruglova, D. M. Demidchik, O. S. Kovalevskaya, Z. Yu. Mutovina, E. A. Dokukina, O. V. Filon, A. V. Petkova, E. K. Khanonina, M. Yu. Samsonov, Д. С. Фомина, С. С. Андреев, Г. В. Андренова, Т. С. Круглова, Д. М. Демидчик, О. С. Ковалевская, З. Ю. Мутовина, Е. А. Докукина, О. В. Филон, А. В. Петкова, Е. К. Ханонина, М. Ю. Самсонов

المساهمون: The study was sponsored by R-Pharm group of companies., Исследование проводилось при финансировании Группы компаний «Р-Фарм».

المصدر: PULMONOLOGIYA; Том 33, № 5 (2023); 623-632 ; Пульмонология; Том 33, № 5 (2023); 623-632 ; 2541-9617 ; 0869-0189

مصطلحات موضوعية: интерлейкин-6, new coronavirus infection (COVID-19), Janus kinase inhibitors, acute respiratory distress syndrome, interleukin-6, новая коронавирусная инфекция (COVID-19), ингибиторы янус-киназ, острый респираторный дистресссиндром

وصف الملف: application/pdf

العلاقة: https://journal.pulmonology.ru/pulm/article/view/4370/3565Test; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4370/2227Test; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4370/2228Test; Woolf S.H., Chapman D.A., Lee J. H. COVID-19 as the leading cause of death in the United States. JAMA. 2021; 325 (2): 123–124. DOI:10.1001/jama.2020.24865.; COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Available at: https://coronavirus.jhu.edu/map.htmlTest [Accessed: September 04, 2023].; ARDS Definition Task Force; Ranieri V.M., Rubenfeld G.D., Thompson B.T. et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012; 307 (23): 2526–2533. DOI:10.1001/jama.2012.5669.; Yang X., Yu Y., Xu J. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 2020; 8 (5): 475–481. DOI:10.1016/s2213-2600(20)30079-5.; Ochani R.K., Asad A., Yasmin F. et al. COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management. Infez. Med. 2021; 29 (1): 20–36. Available at: https://www.infezmed.it/media/journal/Vol_29_1_2021_3.pdfTest; Chilamakuri R., Agarwal S. COVID-19: characteristics and therapeutics. Cells. 2021; 10 (2): 206. DOI:10.3390/cells10020206.; Zhang J., Dong X., Liu G.H., Gao Y.D. Risk and protective factors for COVID-19 morbidity, severity, and mortality. Clin. Rev. Allergy Immunol. 2023; 64 (1): 90–107. DOI:10.1007/s12016-022-08921-5.; National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. 2020. Available at: https://www.covid19treatmentguidelines.nih.govTest/; Министерство здравоохранения Российской Федерации. Временные методические рекомендации: Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 17 (14.12.2022). Доступно на: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/061/252/original/%D0%92%D0%9C%D0%A0_COVID-19_V17.pdfTest [Дата обращения: 06.09.23].; https://journal.pulmonology.ru/pulm/article/view/4370Test

الإتاحة: https://doi.org/10.18093/0869-0189-2023-33-5-623-632Test
https://doi.org/10.1001/jama.2020.24865Test
https://doi.org/10.1001/jama.2012.5669Test
https://doi.org/10.1016/s2213-2600Test(20)30079-5
https://doi.org/10.3390/cells10020206Test
https://doi.org/10.1007/s12016-022-08921-5Test
https://journal.pulmonology.ru/pulm/article/view/4370Test

المؤلفون: R. A. Oseshnyuk, A. G. Nikiforova, A. Yu. Boroduleva, P. D. Sobolev, S. A. Lesnichuk, B. B. Garyaev, A. A. Abramova, V. G. Mozgovaya, O. V. Filon, A. V. Zinkovskaya, A. N. Dolgorukova, E. K. Khanonina, V. G. Ignatiev, M. Yu. Samsonov, Р. А. Осешнюк, А. Г. Никифорова, А. Ю. Бородулева, П. Д. Соболев, С. А. Лесничук, Б. Б. Гаряев, А. А. Абрамова, В. Г. Мозговая, О. В. Филон, А. В. Зинковская, А. Н. Долгорукова, Е. К. Ханонина, В. Г. Игнатьев, М. Ю. Самсонов

المساهمون: The work was carried out with the financing of the R-Pharm group., Работа выполнялась при финансировании группы компаний АО «Р-Фарм».

المصدر: Pharmacy & Pharmacology; Том 11, № 1 (2023); 62-71 ; Фармация и фармакология; Том 11, № 1 (2023); 62-71 ; 2413-2241 ; 2307-9266 ; undefined

مصطلحات موضوعية: воспроизведенный препарат, bioequivalence, pharmacokinetics, nirmatrelvir, ritonavir, generic drug, биоэквивалентность, фармакокинетика, нирматрелвир, ритонавир

وصف الملف: application/pdf

العلاقة: https://www.pharmpharm.ru/jour/article/view/1259/951Test; https://www.pharmpharm.ru/jour/article/view/1259/952Test; Joyce R.P., Hu V.W., Wang J. The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations // Med. Chem. Res. – 2022. – Vol. 31, No. 10. – P. 1637–1646. DOI:10.1007/s00044-022-02951-6; Vangeel L., Chiu W., De Jonghe S., Maes P., Slechten B., Raymenants J., André E., Leyssen P., Neyts J., Jochmans D. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern // Antiviral. Res. – 2022. – Vol. 198. – Art. ID: 105252. DOI:10.1016/j.antiviral.2022.105252; Marzi M., Vakil M.K., Bahmanyar M., Zarenezhad E. Paxlovid: Mechanism of Action, Synthesis, and In Silico Study // Biomed. Res. Int. – 2022. – Vol. 2022. – Art. ID: 7341493. DOI:10.1155/2022/7341493; Singh R.S.P., Toussi S.S., Hackman F., Chan P.L., Rao R., Allen R., Van Eyck L., Pawlak S., Kadar E.P., Clark F., Shi H., Anderson A.S., Binks M., Menon S., Nucci G., Bergman A. Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir // Clin. Pharmacol. Ther. – 2022. – Vol. 112, No. 1. – P. 101–111. DOI:10.1002/cpt.2603; Catlin N.R., Bowman C.J., Campion S.N., Cheung J.R., Nowland W.S., Sathish J.G., Stethem C.M., Updyke L., Cappon G.D. Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 Mpro inhibitor in animal models // Reprod. Toxicol. – 2022. – Vol. 108. – P. 56–61. DOI:10.1016/j.reprotox.2022.01.006; Jeong J.H., Chokkakula S., Min S.C., Kim B.K., Choi W.S., Oh S., Yun Y.S., Kang D.H., Lee O.J., Kim E.G., Choi J.H., Lee J.Y., Choi Y.K., Baek Y.H., Song M.S. Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice // Antiviral. Res. – 2022. – Vol. 208. – Art. ID: 105430. DOI:10.1016/j.antiviral.2022.105430; Greasley S.E., Noell S., Plotnikova O., Ferre R., Liu W., Bolanos B., Fennell K., Nicki J., Craig T., Zhu Y., Stewart A.E., Steppan C.M. Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants // J. Biol. Chem. – 2022. – Vol. 298, No. 6. – Art. ID: 101972. DOI:10.1016/j.jbc.2022.101972; Owen D.R., Allerton C.M.N., Anderson A.S., Aschenbrenner L., Avery M., Berritt S., Boras B., Cardin R.D., Carlo A., Coffman K.J., Dantonio A., Di L., Eng H., Ferre R., Gajiwala K.S., Gibson S.A., Greasley S.E., Hurst B.L., Kadar E.P., Kalgutkar A.S., Lee J.C., Lee J., Liu W., Mason S.W., Noell S., Novak J.J., Obach R.S., Ogilvie K., Patel N.C., Pettersson M., Rai D.K., Reese M.R., Sammons M.F., Sathish J.G., Singh R.S.P., Steppan C.M., Stewart A.E., Tuttle J.B., Updyke L., Verhoest P.R., Wei L., Yang Q., Zhu Y. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 // Science. – 2021. – Vol. 374, No. 6575. – P. 1586–1593. DOI:10.1126/science.abl4784; Wen W., Chen C., Tang J., Wang C., Zhou M., Cheng Y., Zhou X., Wu Q., Zhang X., Feng Z., Wang M., Mao Q. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis // Ann. Med. – 2022. – Vol. 54, No. 1. – P. 516–523. DOI:10.1080/07853890.2022.2034936; Drożdżal S., Rosik J., Lechowicz K., Machaj F., Szostak B., Przybyciński J., Lorzadeh S., Kotfis K., Ghavami S., Łos M.J. An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment // Drug Resist. Updat. – 2021. – Vol. 59. – Art. ID: 100794. DOI:10.1016/j.drup.2021.100794; Hammond J., Leister-Tebbe H., Gardner A., Abreu P., Bao W., Wisemandle W., Baniecki M., Hendrick V.M., Damle B., Simón-Campos A., Pypstra R., Rusnak J.M.; EPIC-HR Investigators. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 // N. Engl. J. Med. – 2022. – Vol. 386, No. 15. – P. 1397–1408. DOI:10.1056/NEJMoa2118542; Wong C.K.H., Au I.C.H., Lau K.T.K., Lau E.H.Y., Cowling B.J., Leung G.M. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study // Lancet. – 2022. – Vol. 400, No. 10359. – P. 1213–1222. DOI:10.1016/S0140-6736(22)01586-0; Wong C.K.H., Au I.C.H., Lau K.T.K., Lau E.H.Y., Cowling B.J., Leung G.M. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong’s omicron BA.2 wave: a retrospective cohort study // Lancet Infect. Dis. – 2022. – Vol. 22, No. 12. – P. 1681–1693. DOI:10.1016/S1473-3099, No. 22)00507-2; Najjar-Debbiny R., Gronich N., Weber G., Khoury J., Amar M., Stein N., Goldstein L.H., Saliba W. Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients // Clin. Infect. Dis. – 2023. – Vol. 76, No. 3. – P. 342–349. DOI:10.1093/cid/ciac443. Erratum in: Clin Infect Dis. – 2023. – Vol. 76, No. 6. – P. 1158–1159.; Dryden-Peterson S., Kim A., Kim A.Y., Caniglia E.C., Lennes I.T., Patel R., Gainer L., Dutton L., Donahue E., Gandhi R.T., Baden L.R., Woolley A.E. Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System: A Population-Based Cohort Study // Ann. Intern. Med. – 2023. – Vol. 176, No. 1. – P. 77–84. DOI:10.7326/M22-2141; Yuan Y., Jiao B., Qu L., Yang D., Liu R. The development of COVID-19 treatment // Front. Immunol. – 2023. – Vol. 14. – Art. ID: 1125246. DOI:10.3389/fimmu.2023.1125246; Zhang J.J., Dong X., Liu G.H., Gao Y.D. Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality // Clin. Rev. Allergy Immunol. – 2023. – Vol. 64, No. 1. – P. 90–107. DOI:10.1007/s12016-022-08921-5; Lipsitch M., Krammer F., Regev-Yochay G., Lustig Y., Balicer R.D. SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact // Nat. Rev. Immunol. – 2022. – Vol. 22, No. 1. – P. 57–65. DOI:10.1038/s41577-021-00662-4; Reis S., Metzendorf M.I., Kuehn R., Popp M., Gagyor I., Kranke P., Meybohm P., Skoetz N., Weibel S. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19 // Cochrane Database Syst. Rev. – 2022. – Vol. 9, No. 9. – Art. ID: CD015395. DOI:10.1002/14651858.CD015395.pub2; Große-Michaelis I., Proestel S., Rao R.M., Dillman B.S., Bader-Weder S., Macdonald L., Gregory W. MedDRA Labeling Groupings to Improve Safety Communication in Product Labels // Ther. Innov. Regul. Sci. – 2023. – Vol. 57, No. 1. – P. 1–6. DOI:10.1007/s43441-022-00393-1; Ullrich S., Nitsche C. The SARS-CoV-2 main protease as drug target // Bioorg. Med. Chem. Lett. – 2020. – Vol. 30, No. 17. – Art. ID: 127377. DOI:10.1016/j.bmcl.2020.127377; Eng H., Dantonio A.L., Kadar E.P., Obach R.S., Di L., Lin J., Patel N.C., Boras B., Walker G.S., Novak J.J., Kimoto E., Singh R.S.P., Kalgutkar A.S. Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans // Drug Metab. Dispos. – 2022. – Vol. 50, No. 5. – P. 576–590. DOI:10.1124/dmd.121.000801; Loos N.H.C., Beijnen J.H., Schinkel A.H. The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism? // Int. J. Mol. Sci. – 2022. – Vol. 23, No. 17. – Art. ID: 9866. DOI:10.3390/ijms23179866; https://www.pharmpharm.ru/jour/article/view/1259Test

الإتاحة: https://doi.org/10.19163/2307-9266-2023-11-1-62-71Test
https://doi.org/10.1007/s00044-022-02951-6Test
https://doi.org/10.1016/j.antiviral.2022.105252Test
https://doi.org/10.1155/2022/7341493Test
https://doi.org/10.1002/cpt.2603Test
https://doi.org/10.1016/j.reprotox.2022.01.006Test
https://doi.org/10.1016/j.antiviral.2022.105430Test
https://doi.org/10.1016/j.jbc.2022.101972Test
https://doi.org/10.1126/science.abl4784Test
https://doi.org/10.1080/07853890.2022.2034936Test